Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2009 | 1 |
2014 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Oncoimmunology. 2021 Jan 4;10(1):1838140. doi: 10.1080/2162402X.2020.1838140.
Oncoimmunology. 2021.
PMID: 33489468
Free PMC article.
In a murine minimal disease model, single and dual immune checkpoint blockade promoted tumor rejection, improved survival, and established immune memory with long-term anti-tumor immunity against re-challenge. In an established tumor model, only dual immune checkpoint bloc …
In a murine minimal disease model, single and dual immune checkpoint blockade promoted tumor rejection, improved survival, and established i …
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM.
Sos ML, et al.
Cell Rep. 2014 Aug 21;8(4):1037-48. doi: 10.1016/j.celrep.2014.07.010. Epub 2014 Aug 7.
Cell Rep. 2014.
PMID: 25127139
Free PMC article.
Overall, we show that the signaling plasticity exerted by primary resistant BRAF-mutant cells is achieved by their ability to mimic signaling features of oncogenic RAS, a strategy that we term "oncogene mimicry." This model may guide future strategies for overcoming primar …
Overall, we show that the signaling plasticity exerted by primary resistant BRAF-mutant cells is achieved by their ability to mimic signalin …
Item in Clipboard
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG.
Matthay KK, et al.
J Clin Oncol. 2009 Mar 1;27(7):1007-13. doi: 10.1200/JCO.2007.13.8925. Epub 2009 Jan 26.
J Clin Oncol. 2009.
PMID: 19171716
Free PMC article.
Clinical Trial.
PURPOSE We assessed the long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were randomly assigned to undergo autologous purged bone marrow transplantation (ABMT) or to receive chemotherapy, and subsequent treatment with 13 …
PURPOSE We assessed the long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were ra …
Item in Clipboard
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS.
Song L, et al.
J Clin Invest. 2007 Sep;117(9):2702-12. doi: 10.1172/JCI30751.
J Clin Invest. 2007.
PMID: 17710228
Free PMC article.
We and others have previously demonstrated positive associations between NKT cell presence in primary tumors and long-term survival in distinct human cancers. However, the mechanism by which aggressive tumors avoid infiltration with NKT and other T cells remains poorly und …
We and others have previously demonstrated positive associations between NKT cell presence in primary tumors and long-term survival i …
Item in Clipboard
Cite
Cite